

# Attachment F

## Covid-19 Grant Outcomes and Accomplishments Final Report

To finalize this award, you are required to provide to the Agency with a narrative of the outcomes and accomplishments related to the funds spent for the specific purpose as stated in the grant contract. You can use the secure link provided below to upload images, brochures, and other information to illustrate your outcomes and accomplishments.

<https://ncosbm.sharefile.com/r-rc7f2ca49d574af2a>

### 1. Organization:

Organization Name:	North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
--------------------	--

### 2. Outcomes and Accomplishments:

**Our Aim for the six-month support period was to provide infrastructure for human cohort recruitment, sample collection, tracking, and sharing.**

In response to the immediate needs of the research and medical community at the UNC-CH and born from collaborations between the UNC-CH Adams School of Dentistry and the UNC-CH School of Medicine, the existing DELTA Translational Services Core was leveraged to establish the **DELTA-COVID Translational Services Initiative**. Dr. Maile and Dr. Wallet are Co-Directors of the DELTA Translational Services Core and engaged Dr. Matt Wolfgang as a co-Director for this Initiative.

**Outcomes:** The funding by the NC Policy Collaboratory provided the initial infrastructure and personnel to rapidly support the clinical sample needs of multiple COVID19-focused projects at UNC and beyond. Importantly, these resources allowed us to set the foundation for sustained support and as such this pipeline of sample acquisition, processing, and storage that we developed has continued. Current projects supported are outlined in **Table 1**.

Services developed and currently provided range from sample collection infrastructure through our Clinical Research Center, sample tracking using our LDMS, sample processing using our BSL2 and BSL2+ facilities, sample storage and shipping (inside UNC and outside UNC), and multi-omics data acquisition and analysis using several technologies/approaches within the DELTA Translational Recharge Center. <https://cytokine.web.unc.edu/>. Our initiative has become GCLP compliant during the funding period allowing us to participate in FDA approved clinical trials etc. Lastly, the types of Sars-CoV-2 samples we have collected and are approved to process are outlined in **Table 2**. We also provide a means for open solicitation of new research projects utilizing our sample source, facilitating full consultation and approval by the Investigator(s) who collected the relevant samples.

As part of the strategic plan to be self-sustainable, we have been able to generate additional funding. For instance, the DELTA-COVID Translational Initiative formed the logistical basis for a successful NIH NCI U54 application (**PIs: Baric / Wallet**). This U54 is a collaboration between the UNC-CH Adams School of Dentistry, UNC-CH School of Public Health and the UNC-CH School of Medicine forming a SeroNet Center of Excellence (**NCI U54CA260543-01** 10/01/20-09/30/25). Additional extramural funding obtained and pending because of this initiative are outlined in **Table 3**.

**Table 1. Current COVID19 Sample Collection Studies Supported by DELTA**

Study	PI	UNC Department	UNC School	# samples
AKA	Mock	Pulmonary	Medicine	120
CHATHAM	Khou	Infectious Disease	Medicine	7,173
CO-HOST	Lin	Infectious Disease	Medicine	14,347
COLGATE	Jacox/Cyriaque	OCHS	Dentistry	TBD
COVIDEX	Mock	Pulmonary	Medicine	1,182
COVIP	Bartlet	Infectious Disease	Medicine	1,845
COVPN	Becker-Dreps	Family Medicine	Medicine	TBD
CPB	Hagan	Pulmonary	Medicine	3,531
ESP	Petifor	Epidemiology	Public Health	13,385
HCW	Ciccone	Infectious Disease	Medicine	4,783
MOR1	Jacox/Cyriaque	OCHS	Dentistry	1,096
OBS-C	Bowman	Infectious Disease	Medicine	1,304
OBS-P	Bowman	Infectious Disease	Medicine	144
OWS	Baric	Epidemiology	Public Health	TBD
<b>Total Samples</b>				<b>48,910</b>

**Table 2. Current SARS-CoV-2 Sample Types Collected and Processed by DELTA.**

Abbreviation	Sample Type
ASP	Aspirate
BAL	Bronchoalveolar Lavage
BLD	Blood (Whole)
CEL	PBMC Cells, Viable
CEN	Fresh Cells from a Non-Blood Spec. Type
EXP	Expectorant
NAS	Nasal Strips
PL1	Plasma, Single-Spun
RBC	Red Blood Cells
SAL	Saliva
SER	Serum
STL	Stool
URN	Urine
VTM	Nasal Swabs

**Table 3. Current and Pending Extramural Funding Supporting DELTA.**

Sponsor	PI	Title	Total (Direct/Indirect)
<b>Active</b>			
Eli Lilly	Hagan	COVID19 BioPathogenesis	\$10,000
Pacific Northwest National Labs	Wolfgang	Altered Innate Immune Metabolism in Severely Ill COVID-19 Patients	\$15,000 (free services)
U54 NCI	Baric/Wallet	North Carolina Seronet Center for Excellence	\$11,673,060
Colgate	Jacox/Cyriaque	Antiviral Efficacy and Acceptability of Colgate Therapeutic Antiseptic Mouth Rinses for the Inactivation of Covid Sars-2 Virus	\$417,503
<b>Total Active Dollars</b>			<b>\$12,115,563</b>
<b>Pending</b>			
U01 NCATS	Wallet/Maile	Community Engaged and Driven Programs Aimed at Understanding the Course and Prevention of SARS-CoV-2 Infection in Diverse, Vulnerable Populations Across the Lifespan	\$4,544,161
<b>Total Pending Dollars</b>			<b>\$4,544,161</b>
<b>Total Dollars</b>			<b>\$16,659,724</b>